Review: taking Renvela and Phoslo together


Summary

Drug interactions are reported among people who take Renvela and Phoslo together. This review analyzes the effectiveness and drug interactions between Renvela and Phoslo. It is created by eHealthMe based on reports of 166 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Renvela

Renvela has active ingredients of sevelamer carbonate. It is often used in hyperphosphataemia. (latest outcomes from Renvela 6,325 users)

Phoslo

Phoslo has active ingredients of calcium acetate. It is often used in hyperphosphataemia. (latest outcomes from Phoslo 3,433 users)

On Sep, 20, 2016

166 people who take Renvela, Phoslo are studied.


Number of reports submitted per year:

Renvela and Phoslo drug interactions.

Most common drug interactions over time *:

< 1 month:
  • exfoliative rash
  • pruritus
  • hyperphosphataemia
1 - 6 months:
  • gastritis erosive
  • liver disorder
  • splenomegaly
  • twin pregnancy
  • premature labour
  • atelectasis
  • cardiac arrest
  • death
  • drug exposure during pregnancy
6 - 12 months:
  • peritonitis
  • blood culture positive
  • staphylococcal bacteraemia
1 - 2 years:
  • myocardial infarction
  • gastrointestinal haemorrhage
not specified:
  • nephrogenic systemic fibrosis
  • pain
  • skin tightness
  • skin hypertrophy
  • pruritus
  • dry skin
  • oedema peripheral
  • rash
  • skin induration
  • arthralgia

Most common drug interactions by gender *:

female:
  • nephrogenic systemic fibrosis
  • pain
  • skin tightness
  • pain in extremity
  • arthralgia
  • musculoskeletal stiffness
  • pruritus
  • dyspnoea
  • peritonitis
  • skin hypertrophy
male:
  • pain
  • nephrogenic systemic fibrosis
  • skin tightness
  • skin hypertrophy
  • dry skin
  • oedema peripheral
  • pruritus
  • general physical health deterioration
  • joint range of motion decreased
  • rash

Most common drug interactions by age *:

2-9:
  • anaemia
  • feeling abnormal
10-19:
  • haemoglobin decreased
  • arthralgia
  • blood calcium abnormal
  • blood pressure increased
  • drug effect decreased
  • hypocalcaemia
  • muscle spasms
  • overdose
20-29:
  • atelectasis
  • brown tumour
  • chromatopsia
  • gastritis erosive
  • liver disorder
  • osteoma
  • scotoma
  • splenomegaly
  • vision blurred
30-39:
  • peritonitis
  • nephrogenic systemic fibrosis
  • axonal neuropathy
  • muscle spasms
  • myositis
  • abasia
  • abdominal pain
  • anaemia
  • anhedonia
  • anxiety
40-49:
  • pruritus
  • arthralgia
  • pain
  • dry skin
  • extremity contracture
  • joint stiffness
  • musculoskeletal stiffness
  • nephrogenic systemic fibrosis
  • rash
  • skin fibrosis
50-59:
  • pain
  • general physical health deterioration
  • drug ineffective
  • dry skin
  • nephrogenic systemic fibrosis
  • oedema peripheral
  • skin tightness
  • hernia
  • skin induration
  • fatigue
60+:
  • dyspnoea
  • pleural effusion
  • peripheral arterial occlusive disease
  • angioplasty
  • cough
  • dyspnoea exertional
  • muscular weakness
  • nephrogenic systemic fibrosis
  • pain
  • skin hypertrophy

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Renvela and Phoslo?

On eHealthMe, Renvela (sevelamer carbonate) is often used to treat hyperphosphataemia. Phoslo (calcium acetate) is often used to treat hyperphosphataemia. Find out below the conditions the drugs are used for and how effective they are.


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.